Elimination of Patient Limits for Prescribing Buprenorphine for Treatment of Opioid Use Disorder (OUD) under the Consolidated Appropriations Act (CAA) of 2023

us-doj-guidance-DEA-DC-066Elimination of Patient Limits for Prescribing Buprenorphine for Treatment of Opioid Use Disorder (OUD) under the Consolidated Appropriations Act (CAA) of 2023Guidance

Drug Enforcement Administration
Diversion Control Division
Guidance Document
Title: Elimination of Patient Limits for Prescribing Buprenorphine for Treatment of Opioid Use
Disorder (OUD) under the Consolidated Appropriations Act (CAA) of 2023
Summary: This guidance document provides information regarding the elimination of limitations
on the number of patients with OUD that a practitioner may treat with buprenorphine, as a result of
Congress’s enactment of the CAA. This guidance will be sent via email to all Drug Enforcement
Administration (DEA)-registered pharmacies and practitioners and will be posted on the DEA
guidance portal.
Activity: Prescribing Buprenorphine for OUD
To Whom It Applies: All DEA-Registered Pharmacies and Practitioners
Question: Are there any limitations on the number of patients with OUD that a practitioner may
treat with buprenorphine after the passage of the Consolidated Appropriations Act of 2023 (CAA)?
Answer: After enactment of the CAA,1 there are no longer limitations, under federal law, on the
number of patients with OUD that a practitioner may treat with buprenorphine. On December 29,
2022, President Biden signed into law the CAA which expanded patient access to medications for
OUD. Specifically, Pub. L. No. 117-328, div. FF, tit. I(B), ch. 6, § 1262(a)(1), 136 Stat. 4459, 5681
(2022) amended the Controlled Substances Act by repealing the “DATA-Waiver” requirement
codified in 21 U.S.C. 823(g)(2), which had previously imposed limits or patient caps on the number
of OUD patients a prescriber may treat with buprenorphine. These limits were previously outlined
at 21 U.S.C. 823(g)(2)(B)(iii), and allowed qualified practitioners to treat up to 30, 100, or 275
patients at one time.
Accordingly, previous patient limits under the DATA-Waiver Program no longer apply.
However, practitioners are still required to comply with any applicable state limits regarding
treatment of patients with OUD. Please check state laws for any limitations. You can find contact
information for State Opioid Treatment Authorities here: https://www.samhsa.gov/medication-
assisted-treatment/sota.
The contents of this document do not have the force and effect of law and are not meant to bind
the public in any way. This document is intended only to provide clarity to the public regarding
existing requirements under the law or Department of Justice policies.
EO-DEA263, DEA-DC-066, March 21, 2023
1 Pub. L. No. 117-328, 136 Stat. 4459 (2022).
Complete printed PDF page 1

Continua la tua ricerca in ChatGPT o Claude

Collega Omnilex per cercare nel corpus legale dal tuo assistente IA.